Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

2.50
Hdl Handle:
http://hdl.handle.net/2336/223499
Title:
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Authors:
Blumsohn, A; Marin, F; Nickelsen, T; Brixen, K; Sigurdsson, G; González de la Vera, J; Boonen, S; Liu-Léage, S; Barker, C; Eastell, R
Citation:
Osteoporos Int. 2011, 22(6):1935-46
Issue Date:
Jun-2011
Abstract:
We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely affect the response to teriparatide treatment. Similar bone markers levels are reached after 6 months of treatment. INTRODUCTION: The response of biochemical markers of bone turnover with teriparatide therapy in subjects who have previously received osteoporosis drugs is not fully elucidated. We examined biochemical markers of bone formation in women with osteoporosis treated with teriparatide and determined: (1) whether the response is associated with prior osteoporosis therapy, (2) which marker shows the best performance for detecting a response to therapy, and (3) the correlations between early changes in bone markers and subsequent bone mineral density (BMD) changes after 24 months of teriparatide. METHODS: We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination. Teriparatide (20 μg/day) was administered for up to 24 months. We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months. RESULTS: Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy. The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels. PINP showed the best signal-to-noise ratio. Baseline PINP correlated positively and significantly with BMD response at 24 months. CONCLUSIONS: This study suggests that the long-term responsiveness of bone formation markers to teriparatide is not affected in subjects previously treated with antiresorptive drugs.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092934/?tool=pubmed
Rights:
Archived with thanks to Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Full metadata record

DC FieldValue Language
dc.contributor.authorBlumsohn, Aen_GB
dc.contributor.authorMarin, Fen_GB
dc.contributor.authorNickelsen, Ten_GB
dc.contributor.authorBrixen, Ken_GB
dc.contributor.authorSigurdsson, Gen_GB
dc.contributor.authorGonzález de la Vera, Jen_GB
dc.contributor.authorBoonen, Sen_GB
dc.contributor.authorLiu-Léage, Sen_GB
dc.contributor.authorBarker, Cen_GB
dc.contributor.authorEastell, Ren_GB
dc.date.accessioned2012-05-14T09:44:41Z-
dc.date.available2012-05-14T09:44:41Z-
dc.date.issued2011-06-
dc.date.submitted2012-05-14-
dc.identifier.citationOsteoporos Int. 2011, 22(6):1935-46en_GB
dc.identifier.issn1433-2965-
dc.identifier.pmid20938767-
dc.identifier.doi10.1007/s00198-010-1379-y-
dc.identifier.urihttp://hdl.handle.net/2336/223499-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractWe report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely affect the response to teriparatide treatment. Similar bone markers levels are reached after 6 months of treatment. INTRODUCTION: The response of biochemical markers of bone turnover with teriparatide therapy in subjects who have previously received osteoporosis drugs is not fully elucidated. We examined biochemical markers of bone formation in women with osteoporosis treated with teriparatide and determined: (1) whether the response is associated with prior osteoporosis therapy, (2) which marker shows the best performance for detecting a response to therapy, and (3) the correlations between early changes in bone markers and subsequent bone mineral density (BMD) changes after 24 months of teriparatide. METHODS: We conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination. Teriparatide (20 μg/day) was administered for up to 24 months. We measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months. RESULTS: Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy. The absolute increase at 1 month was lower in previously treated versus treatment-naïve patients, but after 6 months all groups reached similar levels. PINP showed the best signal-to-noise ratio. Baseline PINP correlated positively and significantly with BMD response at 24 months. CONCLUSIONS: This study suggests that the long-term responsiveness of bone formation markers to teriparatide is not affected in subjects previously treated with antiresorptive drugs.en_GB
dc.language.isoenen
dc.publisherSpringer Internationalen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092934/?tool=pubmeden_GB
dc.rightsArchived with thanks to Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAen_GB
dc.subject.meshAgeden_GB
dc.subject.meshAlkaline Phosphataseen_GB
dc.subject.meshBiological Markersen_GB
dc.subject.meshBone Densityen_GB
dc.subject.meshBone Density Conservation Agentsen_GB
dc.subject.meshDrug Substitutionen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshFemur Necken_GB
dc.subject.meshHip Jointen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLumbar Vertebraeen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshOsteogenesisen_GB
dc.subject.meshOsteoporosis, Postmenopausalen_GB
dc.subject.meshPeptide Fragmentsen_GB
dc.subject.meshProcollagenen_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshTeriparatideen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleEarly changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Biochemistry, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.en_GB
dc.identifier.journalOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAen_GB

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.